Ketamine Korner: Edition 7
Ketamine Korner is a bi-weekly newsletter exploring advances in ketamine therapy, originally started by Mind Pain Relief Institute Co-Founder Dr. Rohit Aiyer.
Each edition is republished with permission from Dr. Aiyer.
Latest Research Highlight:
Research Update: A randomized, placebo-controlled Phase 2 trial published in Nature Medicine in June 2024 tested an extended-release oral ketamine formulation (R-107) for treatment-resistant depression (Daly et al., Nature Medicine, 2024).
After a five-day open-label phase, responders (168 of 231 participants) were randomized to continue R-107 or switch to placebo for 12 weeks (Daly et al., Nature Medicine, 2024).
In the double-blind phase, the 180 mg twice-weekly dose showed a statistically significant improvement in depressive symptoms compared with placebo, with a MADRS group difference of 6.1 points at week 13 (Daly et al., Nature Medicine, 2024).
This study is notable because it directly tests a maintenance-style ketamine protocol designed to sustain antidepressant benefits beyond the acute response window (Daly et al., Nature Medicine, 2024).
A Brief History of Ketamine and Durable Response in Depression:
The Rapid-Acting Breakthrough: A landmark randomized trial published in Archives of General Psychiatry showed that a single intravenous ketamine infusion produced rapid antidepressant effects within hours, but benefits often diminished within one to two weeks (Zarate et al., Archives of General Psychiatry, 2006).
Why Maintenance Entered the Conversation: A 2013 repeated-infusion study in treatment-resistant depression found that even among responders, the median time to relapse was 18 days after the final infusion, highlighting the need for continuation strategies (Murrough et al., Biological Psychiatry, 2013).
Prolonging Benefit Became a Research Priority: A systematic review evaluating methods to extend ketamine’s antidepressant effects confirmed that durability of response became a central research question in the 2010s (Wilkinson et al., Journal of Affective Disorders, 2021).
New Directions: The 2024 extended-release oral ketamine trial represents one of the first large controlled studies specifically designed to test longer-term maintenance outcomes rather than single-dose response (Daly et al., Nature Medicine, 2024).
Mythbuster:
Myth: Ketamine only works as a short-lived intravenous treatment, and oral ketamine cannot be studied rigorously.
Reality:
The 2024 Nature Medicine trial used a randomized, placebo-controlled design to evaluate oral extended-release ketamine over 12 weeks, demonstrating that longer-term benefit can be measured under strict clinical conditions (Daly et al., Nature Medicine, 2024).
Earlier infusion studies show why maintenance research matters, since relapse can occur within weeks even after successful infusion series (Murrough et al., Biological Psychiatry, 2013).
Systematic reviews now confirm that sustaining ketamine’s antidepressant response is a key focus of current clinical research, with multiple continuation-strategy trials underway (Wilkinson et al., Journal of Affective Disorders, 2021).
Key Takeaway:
Ketamine’s story is no longer just about rapid relief. The newest generation of trials is focused on staying well, not only feeling better for a few days. As maintenance-oriented research evolves, clinicians are moving closer to evidence-based protocols for durable recovery.